CN107109455B - 用于操控糖蛋白的聚糖含量水平的方法 - Google Patents

用于操控糖蛋白的聚糖含量水平的方法 Download PDF

Info

Publication number
CN107109455B
CN107109455B CN201580071982.6A CN201580071982A CN107109455B CN 107109455 B CN107109455 B CN 107109455B CN 201580071982 A CN201580071982 A CN 201580071982A CN 107109455 B CN107109455 B CN 107109455B
Authority
CN
China
Prior art keywords
cells
cell
cell culture
perfusion
culture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580071982.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN107109455A (zh
Inventor
D.R.莱斯克
M.T.特伦塔兰奇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55024253&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN107109455(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CN107109455A publication Critical patent/CN107109455A/zh
Application granted granted Critical
Publication of CN107109455B publication Critical patent/CN107109455B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C07K16/242—Lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2523/00—Culture process characterised by temperature

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201580071982.6A 2014-12-01 2015-12-01 用于操控糖蛋白的聚糖含量水平的方法 Active CN107109455B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462085759P 2014-12-01 2014-12-01
US62/085759 2014-12-01
PCT/US2015/063271 WO2016089919A1 (en) 2014-12-01 2015-12-01 Process for manipulating the level of glycan content of a glycoprotein

Publications (2)

Publication Number Publication Date
CN107109455A CN107109455A (zh) 2017-08-29
CN107109455B true CN107109455B (zh) 2022-02-18

Family

ID=55024253

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580071982.6A Active CN107109455B (zh) 2014-12-01 2015-12-01 用于操控糖蛋白的聚糖含量水平的方法

Country Status (22)

Country Link
US (5) US10167492B2 (OSRAM)
EP (2) EP3680344A1 (OSRAM)
JP (4) JP6698681B2 (OSRAM)
KR (1) KR102623965B1 (OSRAM)
CN (1) CN107109455B (OSRAM)
AU (5) AU2015355087C1 (OSRAM)
CA (1) CA2969225C (OSRAM)
CL (1) CL2017001369A1 (OSRAM)
CY (1) CY1123247T1 (OSRAM)
DK (1) DK3227454T3 (OSRAM)
EA (2) EA202091598A3 (OSRAM)
ES (1) ES2784503T3 (OSRAM)
HU (1) HUE049201T2 (OSRAM)
IL (2) IL276165B (OSRAM)
LT (1) LT3227454T (OSRAM)
MX (1) MX385409B (OSRAM)
PL (1) PL3227454T3 (OSRAM)
PT (1) PT3227454T (OSRAM)
SG (2) SG11201704351WA (OSRAM)
SI (1) SI3227454T1 (OSRAM)
WO (1) WO2016089919A1 (OSRAM)
ZA (2) ZA201703729B (OSRAM)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202091598A3 (ru) 2014-12-01 2021-01-29 Эмджен Инк. Процесс контроля уровня содержания гликанов в составе
EP4310503A3 (en) 2015-12-30 2024-03-20 Momenta Pharmaceuticals, Inc. Methods related to biologics
JP7672196B2 (ja) * 2017-03-14 2025-05-07 アムジエン・インコーポレーテツド 細胞培養において産生される抗体の総非フコシル化グリコフォームの調節
CN110520538B (zh) * 2017-03-31 2024-02-20 勃林格殷格翰国际公司 灌注培养基
WO2019105444A1 (zh) * 2017-11-30 2019-06-06 正大天晴药业集团南京顺欣制药有限公司 蛋白质的生产方法
EP3775251A1 (en) 2018-03-26 2021-02-17 Amgen Inc. Total afucosylated glycoforms of antibodies produced in cell culture
US20210147532A1 (en) * 2018-05-24 2021-05-20 Ares Trading S.A. Method for controlling the afucosylation level of a glycoprotein composition
EP3802610A1 (en) 2018-06-05 2021-04-14 Amgen Inc. Modulating antibody dependent cellular phagocytosis
MX2021002792A (es) 2018-09-11 2021-05-12 Amgen Inc Metodos para modular la citotoxicidad mediada por celulas dependiente de anticuerpos.
HU231514B1 (hu) * 2018-11-07 2024-07-28 Richter Gedeon Nyrt. Sejttenyészetben előállított rekombináns glikoprotein glikozilációs mintázatának megváltoztatására szolgáló módszer
EP3880824B1 (en) 2018-11-13 2024-07-24 Janssen Biotech, Inc. Control of trace metals during production of anti-cd38 antibodies
BR112021012973A2 (pt) * 2018-12-31 2021-09-14 Momenta Pharmaceuticals, Inc. Métodos de produção de ustequinumabe
AU2020216368B2 (en) * 2019-01-30 2025-04-24 Amgen Inc. Aflibercept attributes and methods of characterizing and modifying thereof
MX2021013628A (es) 2019-05-06 2022-03-07 Amgen Inc Modulación de las funciones efectoras de anticuerpos.
JP2020188737A (ja) * 2019-05-23 2020-11-26 東ソー株式会社 抗体依存性細胞傷害活性が向上した抗体の製造方法
CA3152547A1 (en) 2019-09-26 2021-04-01 Amgen Inc. Methods of producing antibody compositions
WO2022026451A1 (en) * 2020-07-30 2022-02-03 Amgen Inc. Cell culture media and methods of making and using the same
CN116391043A (zh) * 2020-08-14 2023-07-04 百时美施贵宝公司 蛋白质的制造方法
JP2023548767A (ja) 2020-10-15 2023-11-21 アムジエン・インコーポレーテツド 抗体製造方法における相対不対グリカン
WO2022261021A1 (en) 2021-06-07 2022-12-15 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
WO2023161885A1 (en) * 2022-02-25 2023-08-31 Kashiv Biosciences, Llc A process for improving polypeptide expression in mammalian cell culture
AU2024256160A1 (en) 2023-04-20 2025-10-02 Amgen Inc. Methods of determining relative unpaired glycan content
WO2025036924A1 (en) * 2023-08-16 2025-02-20 Glaxosmithkline Intellectual Property Limited Method of controlling antibody glycosylation profile

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101061231A (zh) * 2004-08-27 2007-10-24 惠氏研究爱尔兰有限公司 TNFR－Ig融合蛋白的生产

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
AU588819B2 (en) 1984-10-29 1989-09-28 Immunex Corporation Cloning of human granulocyte-macrophage colony stimulating factor gene
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
DE10399023I2 (de) 1989-09-12 2006-11-23 Ahp Mfg B V TFN-bindende Proteine
US6204363B1 (en) 1989-10-16 2001-03-20 Amgen Inc. Stem cell factor
US5149792A (en) 1989-12-19 1992-09-22 Amgen Inc. Platelet-derived growth factor B chain analogs
US5272064A (en) 1989-12-19 1993-12-21 Amgen Inc. DNA molecules encoding platelet-derived growth factor B chain analogs and method for expression thereof
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
US5096816A (en) 1990-06-05 1992-03-17 Cetus Corporation In vitro management of ammonia's effect on glycosylation of cell products through pH control
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
US6284471B1 (en) * 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
JP3589665B2 (ja) 1992-10-23 2004-11-17 イミュネックス・コーポレーション 可溶性オリゴマー蛋白質の調製法
US5554512A (en) 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
US5981713A (en) 1994-10-13 1999-11-09 Applied Research Systems Ars Holding N.V. Antibodies to intereleukin-1 antagonists
US5721121A (en) 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
KR100510234B1 (ko) 1995-06-29 2005-11-25 임뮤넥스 코포레이션 세포소멸을 유도하는 시토킨
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US6096728A (en) 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6337072B1 (en) 1998-04-03 2002-01-08 Hyseq, Inc. Interleukin-1 receptor antagonist and recombinant production thereof
US6528286B1 (en) 1998-05-29 2003-03-04 Genentech, Inc. Mammalian cell culture process for producing glycoproteins
JP2001120262A (ja) 1999-10-26 2001-05-08 Welfide Corp 生理活性物質の産生増強方法
AU1920301A (en) 1999-11-17 2001-05-30 Immunex Corporation Receptor activator of nf-kappa b
US6544424B1 (en) 1999-12-03 2003-04-08 Refined Technology Company Fluid filtration system
DE60104282T2 (de) 2000-05-26 2005-10-13 Bristol-Myers Squibb Co. Lösliche mutante ctla4 moleküle und deren verwendung
EP1498491A4 (en) 2002-04-09 2006-12-13 Kyowa Hakko Kogyo Kk METHOD FOR ENHANCING ACTIVITY OF BINDING ANTIBODY COMPOSITION WITH FC GAMMA IIIA RECEPTOR
DE10312765A1 (de) 2003-03-21 2004-09-30 Bayer Technology Services Gmbh Vorrichtung und Verfahren zur Sterilisation flüssiger Medien mittels UV-Bestrahlung und Kurzzeiterhitzung
TWI384069B (zh) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
US8053238B2 (en) 2005-10-31 2011-11-08 Unhwa Corporation Isolated population of plant single cells and method of preparing the same
US20070231895A1 (en) 2005-11-02 2007-10-04 Lee Gene W Methods for adapting mammalian cells
AU2006324163B2 (en) 2005-12-08 2013-05-02 Amgen Inc. Improved production of glycoproteins using manganese
WO2007081031A1 (ja) * 2006-01-16 2007-07-19 Hokkaido University 糖転移酵素阻害剤
WO2008008482A2 (en) * 2006-07-13 2008-01-17 Genentech, Inc. Altered br3-binding polypeptides
DK2041270T3 (da) 2006-07-13 2014-01-27 Wyeth Llc Fremstilling af glycoproteiner
FR2904558B1 (fr) * 2006-08-01 2008-10-17 Lab Francais Du Fractionnement "composition de facteur vii recombinant ou transgenique, presentant majoritairement des formes glycanniques biantennees, bisialylees et non fucosylees"
EP2064315B1 (en) 2006-11-03 2015-05-13 Wyeth LLC Glycolysis-inhibiting substances in cell culture
US9012180B2 (en) 2007-03-02 2015-04-21 Wyeth Llc Use of copper and glutamate in cell culture for production of polypeptides
US20100028904A1 (en) * 2007-03-30 2010-02-04 Centocor, Inc. Way to obtain high expression clones of mammalian cells using a methylcellulose with fluorescent protein a or g and fluorescent screening method
PT2137655E (pt) 2007-04-16 2012-09-14 Momenta Pharmaceuticals Inc Produtos de glicoproteína definidos e métodos relacionados
WO2008154014A2 (en) 2007-06-11 2008-12-18 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production
WO2008157247A1 (en) 2007-06-15 2008-12-24 Amgen Inc. Methods of treating cell culture media for use in a bioreactor
CA2763164A1 (en) 2009-06-05 2010-12-09 Momenta Pharmaceuticals, Inc. Methods of modulating fucosylation of glycoproteins
KR20140032944A (ko) 2010-10-20 2014-03-17 모르포테크, 인크. 항폴레이트 수용체 알파 항체 당형태
SG192905A1 (en) 2011-02-23 2013-09-30 Amgen Inc Cell culture media for uvc exposure and methods related thereto
AU2012226398B9 (en) * 2011-03-06 2017-04-13 Merck Serono S.A. Low fucose cell lines and uses thereof
US9133493B2 (en) 2011-04-21 2015-09-15 Amgen Inc. Method for culturing mammalian cells to improve recombinant protein production
US9062106B2 (en) * 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
JP5897708B2 (ja) 2011-07-01 2016-03-30 アムジエン・インコーポレーテツド 哺乳類細胞培養物
AR087433A1 (es) * 2011-08-08 2014-03-26 Merck Sharp & Dohme Analogos de insulina n-glicosilados
KR101710766B1 (ko) 2011-09-16 2017-02-27 암젠 인크 세포 배양물의 사전-예정된 비-피이드백 조절된 연속 공급
KR102091294B1 (ko) 2011-10-26 2020-04-16 암젠 인크 Uv 광으로의 노출로 인한 단백질 변형 및 분해의 감소 또는 제거 방법
CN104487570A (zh) * 2012-01-20 2015-04-01 新加坡科技研究局 Cho-gmt重组蛋白的表达
WO2013114245A1 (en) * 2012-01-30 2013-08-08 Dr. Reddy's Laboratories Limited Process of modulating man5 and/or afucosylation content of glycoprotein composition
WO2013114164A1 (en) * 2012-01-30 2013-08-08 Dr. Reddy's Laboratories Limited Method for obtaining glycoprotein composition with increased afucosylation content
US10955291B2 (en) 2012-03-15 2021-03-23 Amgen Inc. Methods of determining exposure to UV light
US10481164B2 (en) 2012-03-26 2019-11-19 Amgen Inc. Method for using light scattering in real time to directly monitor and control impurity removal in purification processes
ES2773107T3 (es) * 2012-10-05 2020-07-09 Kyowa Kirin Co Ltd Composición de proteína heterodimérica
US8956830B2 (en) 2013-03-14 2015-02-17 Momenta Pharmaceuticals, Inc. Methods of cell culture
US9677105B2 (en) 2013-03-14 2017-06-13 Momenta Pharmaceuticals, Inc. Methods of cell culture
KR102062784B1 (ko) * 2013-07-23 2020-01-07 바이오콘 리미티드 단백질 내 푸코실화 수준을 제어하는 방법
PT3110961T (pt) * 2014-02-27 2020-01-29 Hoffmann La Roche Modulação do crescimento celular e da glicosilação na produção de glicoproteínas recombinantes
WO2016068799A1 (en) * 2014-10-27 2016-05-06 Agency For Science, Technology And Research Methods of recombinant protein expression in a cell comprising reduced udp-galactose transporter activity
EA202091598A3 (ru) 2014-12-01 2021-01-29 Эмджен Инк. Процесс контроля уровня содержания гликанов в составе

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101061231A (zh) * 2004-08-27 2007-10-24 惠氏研究爱尔兰有限公司 TNFR－Ig融合蛋白的生产

Also Published As

Publication number Publication date
DK3227454T3 (da) 2020-04-14
AU2015355087C1 (en) 2025-10-30
BR112017011652A2 (pt) 2018-06-26
KR20170083636A (ko) 2017-07-18
US20170362625A1 (en) 2017-12-21
AU2025223948A1 (en) 2025-09-18
US20210017565A1 (en) 2021-01-21
EA036178B1 (ru) 2020-10-09
AU2015355087B2 (en) 2020-04-09
CA2969225C (en) 2023-08-22
EA202091598A2 (ru) 2020-10-30
EP3680344A1 (en) 2020-07-15
IL252569A0 (en) 2017-07-31
IL276165B (en) 2022-11-01
LT3227454T (lt) 2020-07-27
CA2969225A1 (en) 2016-06-09
CY1123247T1 (el) 2021-10-29
AU2015355087A1 (en) 2017-06-29
PL3227454T3 (pl) 2020-07-27
AU2022200586A1 (en) 2022-02-24
ES2784503T3 (es) 2020-09-28
US20230159974A1 (en) 2023-05-25
HUE049201T2 (hu) 2020-09-28
MX2017006997A (es) 2017-10-16
WO2016089919A1 (en) 2016-06-09
US10822630B2 (en) 2020-11-03
PT3227454T (pt) 2020-04-06
CN107109455A (zh) 2017-08-29
SG11201704351WA (en) 2017-06-29
AU2020202302A1 (en) 2020-04-23
IL252569B (en) 2020-08-31
JP6698681B2 (ja) 2020-05-27
ZA202006002B (en) 2022-03-30
CL2017001369A1 (es) 2018-02-23
JP2020124216A (ja) 2020-08-20
JP2017538446A (ja) 2017-12-28
US20200172947A1 (en) 2020-06-04
JP2024095777A (ja) 2024-07-10
MX385409B (es) 2025-03-04
JP7066775B2 (ja) 2022-05-13
KR102623965B1 (ko) 2024-01-11
EA202091598A3 (ru) 2021-01-29
IL276165A (en) 2020-09-30
EP3227454B1 (en) 2020-01-29
US10167492B2 (en) 2019-01-01
EP3227454A1 (en) 2017-10-11
JP2022101669A (ja) 2022-07-06
US20190085370A1 (en) 2019-03-21
SG10202002458PA (en) 2020-04-29
EA201791223A1 (ru) 2017-10-31
ZA201703729B (en) 2021-03-31
AU2024204313A1 (en) 2024-07-11
SI3227454T1 (sl) 2020-06-30

Similar Documents

Publication Publication Date Title
US20230159974A1 (en) Process for manipulating the level of glycan content of a glycoprotein
US11427848B2 (en) Methods for harvesting mammalian cell cultures
HK40034016A (en) Process for manipulating the level of glycan content of a glycoprotein
HK40065682A (en) Methods for harvesting mammalian cell cultures
HK40065682B (en) Methods for harvesting mammalian cell cultures
HK40014805B (en) Methods for harvesting mammalian cell cultures
HK40014805A (en) Methods for harvesting mammalian cell cultures
BR112017011652B1 (pt) Método para manipulação do nível de teor de glicano fucosilado em uma proteína recombinante
HK1236575A1 (en) Methods for harvesting mammalian cell cultures
HK1236575B (en) Methods for harvesting mammalian cell cultures

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant